Practical implication
Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.
FDA, in partnership with the International Coalition of Medicines Regulatory Authorities (ICMRA), has finalized an assessment of a new recombinant endotoxins testing approach that aims to reduce the reliance on horseshoe crab blood for biological products. This assessment is part of the ICMRA Collaborative Assessment Pilot, which enables simultaneous review of manufacturing changes by multiple international regulators.
What changed: The new testing method for endotoxins is now approved as an alternative to the traditional Limulus Amebocyte Lysate (LAL) test, allowing for the use of recombinant endotoxins testing without horseshoe crab-derived materials.
Why it matters: This change supports animal welfare by reducing reliance on animal-derived materials, aligns with FDA's commitment to modernizing pharmaceutical testing, and enhances global regulatory coordination, thereby facilitating more timely patient access to medicines.
Practical implication: Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-08-31T00:00:00.000Z
- Discovered by monitor: 2026-08-31T21:32:30.489Z
Published from the regulator source ingestion pipeline after PV impact triage.
